Compugen Ltd. Earnings Recaps
Q3 2025
Nov 10, 2025
Compugen reported strong fundamentals in Q3 2025, driven by its innovation in Fc reduced anti-TIGIT treatments and promising clinical developments aimed at redefining cancer therapy.
Key takeaways
- Introduction of COM902, a fully owned Fc reduced anti-TIGIT monoclonal antibody, highlights Compugen's strategic advantage over Fc active competitors in clinical efficacy and safety.
- Partnership with AstraZeneca on rilfrogostomy positions Compugen to benefit from a substantial commercial opportunity, with peak year revenue estimates exceeding $5 billion.
- COM701, the only Fc reduced anti-PVRIG antibody in clinical development, targets unmet medical needs in platinum-sensitive ovarian cancer, enhancing Compugen's diverse pipeline.
- Potential milestone payments of $758 million through the Gilead partnership on the innovative GS0321 program showcase significant financial upside.
- Upcoming data readouts from key programs anticipated in 2026 could catalyze investment interest and market recognition for Compugen’s unique therapies.